Precision Cancer Company Accent Therapeutics Launches with $40 Million Series A Round

Precision Cancer Company Accent Therapeutics Launches with $40 Million Series A Round

Source: 
CP Wire
snippet: 

Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, today announced $40 million in Series A capital to establish a discovery platform and pipeline of therapeutic candidates targeting RNA-modifying proteins (RMPs), a novel target space for precision cancer therapies. The Column Group, Atlas Venture and EcoR1 Capital provided the investment.